Patents Examined by Heidi Reese
  • Coelenterazine analogues
    Patent number: 10669280
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: June 2, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Mary Hall, Thomas Kirkland, Thomas Machleidt, Anton Shakhmin, Joel R. Walker
  • Artificial skin culture container and method for producing artificial skin using same
    Patent number: 10669527
    Abstract: An artificial skin culture container according to the present invention can solve the problems of the contraction of the dermal layer of artificial skin and the detachment thereof from the culture container, which result from an interaction between collagen and fibroblasts existing in the dermal layer of artificial skin during the production of the artificial skin, by using agar and hydrophobically modifying a portion of the agar. Therefore, the use of the culture container enables to stably culture artificial skin and produce artificial skin similar to the human skin. In addition, the artificial skin culture container of the present invention comprises agar, and thus a culture solution can be supplied through a side portion as well as a lower portion of the culture container, which allows to effectively culture artificial skin.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: June 2, 2020
    Assignees: AMOREPACIFIC CORPORATION, SOONGSIL UNIVERSITY RESEARCH CONSORTIUM TECHNO-PARK
    Inventors: Dae Jin Min, Sung Hoon Lee, Hae Kwang Lee, Jae Hyun Jeong, Hee Wook Ryu, Hee Jin Kim
  • Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
    Patent number: 10669257
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 2, 2020
    Assignee: Celgene Corporation
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • Method of enumerating coliform colonies
    Patent number: 10662460
    Abstract: A method of enumerating gas-producing coliform bacteria present in a cultured dairy product is provided. The method can comprise forming a mixture that comprises a predefined quantity of the dairy product and a predefined volume of a diluent; inoculating a thin film culture device with the mixture to form a hydrogel comprising a nutrient medium for growing coliform bacteria, an effective concentration of lactose, and an effective concentration of MOPS; incubating the inoculated thin film culture device under conditions that facilitate growth of a coliform bacterium; and identifying and counting a gas-producing colony present in the inoculated culture device.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: May 26, 2020
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventor: Patrick A. Mach
  • Method for producing a medium containing steroidal glycosides from plant cells of the genus
    Patent number: 10660925
    Abstract: A method for producing an active ingredient-containing medium from cultured plant cells, selected from the Hoodia genus, is provided. The method comprises the steps of: (i) incubating a mixture of cultured plant cells of the genus Hoodia and a liquid media in light; (ii) separating the incubated mixture into a first portion and a second portion; (iii) passing the first portion through a tangential flow filter to produce a filtrate containing only media and a retentate containing cultured plant cells; (iv) passing the filtrate through a nano-filter to obtain a nano-retentate having a high concentration of steroidal glycosides; (v) reintroducing some of the nano-retentate into the second portion; and (vi) repeating steps (i) to (v) using the second portion. The medium may be either plant cells or a plant extract.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: May 26, 2020
    Assignee: LYKKE RESEARCH LIMITED
    Inventor: Peter Andrew Whitton
  • 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
    Patent number: 10653688
    Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: May 19, 2020
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar Kc, Chi Ching Mak, Brian Joseph Hofilena, Gopi Kumar Mittapalli, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Chandramouli Chiruta
  • Biaryl derivative and medicine containing same
    Patent number: 10647675
    Abstract: Provided is a compound showing excellent Antifungal activity against Trichophyton fungus, which is a major causative microorganism of superficial mycosis, and high effectiveness on diseases caused by Trichophyton fungi. A biaryl derivative represented by the formula (I) or a salt thereof: wherein ring A is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered ring heteroaryl (ring A may be further condensed to form an optionally substituted fused ring); Q is CH2, C?O, NH, O, S or the like; X1, X2 and X3 are CR1 or N; Y is CH or N; Z is CR2b or N; R2a and R2b are each a hydrogen atom, a halogen atom, an optionally substituted C1-C6 alkyl group, a C1-C6 haloalkyl group or the like; R2a and R2b may form, together with carbon atoms bonded thereto, an optionally substituted carbocycle, or an optionally substituted heterocycle.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: May 12, 2020
    Assignee: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Watanabe, Yuuki Sato, Keiji Ogura, Yoshiyuki Tatsumi
  • Analogues of hydroxychloroquine (HCQ) without retinal toxicity
    Patent number: 10647677
    Abstract: The present invention relates to hydroxychloroquine analogues having an activity superior to that of hydroxychloroquine but free from retinal cytotoxicity of formula (I), their pharmaceutically acceptable salts, solvates or hydrates: their method of preparation and their use in the treatment of lupus erythematosus.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: May 12, 2020
    Assignees: INOVIEM SCIENTIFIC, UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE INTERNATIONAL DE RECHERCHE AUX FRONTIERES DE LA CHIME
    Inventors: Anne-Sophie Korganow, Pierre Eftekhari, Alain Wagner, Corinne Baehr
  • Anthracene based compounds and their uses
    Patent number: 10640466
    Abstract: A compound of the general formula (A) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, stereoisomer or mixture thereof, in which: X is independently NO2 or H; and Y is selected from H, amino, amide, ester, carboxy and its esters and amides, alkyl, alkenyl, alkynyl, cycloalkyl, alkaryl, aryl, heterocyclic or heteroaryl groups, all of which can be substituted with heteroatoms and/or side groups, and wherein any chains can be straight or branched is disclosed.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: May 5, 2020
    Assignee: UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION
    Inventors: Sharon Rossiter, Stewart Brian Kirton, Ramatoulie Camara
  • Farnesoid X receptor agonists and uses thereof
    Patent number: 10626081
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 21, 2020
    Assignee: METACRINE, INC.
    Inventors: Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
  • Compounds for the treatment of cancer
    Patent number: 10618930
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 14, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Ligand-enabled meta-C-H activation using a transient mediator
    Patent number: 10611723
    Abstract: An alternative approach to formation of a C—C bond at a meta-position of an aromatic compound is disclosed that employs an ethylenically unsaturated bicyclic compound as a transient mediator to achieve meta-selective C—H activation with a simple and common ortho-directing group. The use of a pyridine-based ligand assists in relaying the palladium catalyst to the meta-position by the unsaturated bicyclic compound following initial ortho-C—H activation.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 7, 2020
    Assignee: The Scripps Research Institute
    Inventor: Jin-Quan Yu
  • Process and method for stillage fermentation
    Patent number: 10588279
    Abstract: The present invention generally relates to a novel process in which thin stillage is processed to produce algae oil and protein rich biomass as well as other energy rich byproducts. In accordance with a preferred embodiment, thin stillage is removed from an evaporator during the evaporation process to produce mid-stillage. This mid-stillage is preferably routed to a new process where it is directed to a pre-treatment centrifuge to remove suspended solids, sludge and corn oil. Thereafter, the mid-stillage is preferably cooled and then directed to a fermentation tank where the mid-stillage is subject to a batch fermentation process with algae “seed” fed from an algae inoculation system. Once the batch is harvested, the oil-rich algae/mid-stillage is then preferably heated to rupture the cells and liberate the oil.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 17, 2020
    Assignee: BIOPROCESS ALGAE LLC
    Inventor: Adam Crotteau
  • Compositions and methods for treatment of fragile X syndrome
    Patent number: 10588905
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: March 17, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Heterocyclic compound and use thereof
    Patent number: 10584097
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: March 10, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Pyrazole compounds and methods of use thereof
    Patent number: 10584119
    Abstract: The present invention comprises compounds of Formula I and their use in the inhibition of cell proliferation in therapeutic treatments. Pharmaceutical compositions comprising at least one compound of Formula I and at least one pharmaceutical excipient are disclosed, as well as methods of using compounds of Formula I and pharmaceutical compositions thereof for treatment of hyper-proliferative diseases and other disorders.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: March 10, 2020
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • Histone deacetylase as a modulator of PDLI expression and activity
    Patent number: 10576066
    Abstract: Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a therapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: March 3, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Alejandro V. Villagra, Eduardo M. Sotomayor
  • Quinolinones as inhibitors of translation initiation complex
    Patent number: 10577349
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: March 3, 2020
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Ze'ev Ronai, Anthony B. Pinkerton, Yongmei Feng, Ivan Topisirovic, Kevin Brown, Christian A. Hassig
  • Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
    Patent number: 10577344
    Abstract: The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: March 3, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jef DeBrabander, Jerry W. Shay, Wentian Wang
  • Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
    Patent number: 10577365
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 3, 2020
    Assignees: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova